» Articles » PMID: 26709417

A Mathematical Model of the Pathogenesis, Prevention, and Reversal of Type 2 Diabetes

Overview
Journal Endocrinology
Specialty Endocrinology
Date 2015 Dec 29
PMID 26709417
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Type 2 diabetes (T2D) is generally thought to result from the combination of 2 metabolic defects, insulin resistance, which increases the level of insulin required to maintain glucose within the normal range, and failure of insulin-secreting pancreatic β-cells to compensate for the increased demand. We build on a mathematical model pioneered by Topp and colleagues to elucidate how compensation succeeds or fails. Their model added a layer of slow negative feedback to the classic insulin-glucose loop in the form of a slow, glucose-dependent birth and death law governing β-cell mass. We add to that model regulation of 2 aspects of β-cell function on intermediate time scales. The model quantifies the relative contributions of insulin action and insulin secretion defects to T2D and explains why prevention is easier than cure. The latter is a consequence of a threshold separating the normoglycemic and diabetic states (bistability), which also underlies the success of bariatric surgery and acute caloric restriction in rapidly reversing T2D. The threshold concept gives new insight into "Starling's Law of the Pancreas," whereby insulin secretion is higher for prediabetics and early diabetics than for normal individuals.

Citing Articles

The Causal Role of Ectopic Fat Deposition in the Pathogenesis of Metabolic Syndrome.

Janssen J Int J Mol Sci. 2025; 25(24.

PMID: 39769002 PMC: 11675790. DOI: 10.3390/ijms252413238.


A mathematical model for ketosis-prone diabetes suggests the existence of multiple pancreatic β-cell inactivation mechanisms.

Ridout S, Vellanki P, Nemenman I bioRxiv. 2024; .

PMID: 38895272 PMC: 11185683. DOI: 10.1101/2024.06.04.597343.


Estimating insulin sensitivity and β-cell function from the oral glucose tolerance test: validation of a new insulin sensitivity and secretion (ISS) model.

Ha J, Chung S, Springer M, Kim J, Chen P, Chhabra A Am J Physiol Endocrinol Metab. 2023; 326(4):E454-E471.

PMID: 38054972 PMC: 11639675. DOI: 10.1152/ajpendo.00189.2023.


A data-driven computational model for obesity-driven diabetes onset and remission through weight loss.

Yildirim V, Sheraton V, Brands R, Crielaard L, Quax R, Van Riel N iScience. 2023; 26(11):108324.

PMID: 38026205 PMC: 10665812. DOI: 10.1016/j.isci.2023.108324.


Steady solution and its stability of a mathematical model of diabetic atherosclerosis.

Xie X J Biol Dyn. 2023; 17(1):2257734.

PMID: 37711027 PMC: 10576982. DOI: 10.1080/17513758.2023.2257734.


References
1.
Topp B, Promislow K, deVries G, Miura R, Finegood D . A model of beta-cell mass, insulin, and glucose kinetics: pathways to diabetes. J Theor Biol. 2000; 206(4):605-19. DOI: 10.1006/jtbi.2000.2150. View

2.
Henquin J . Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes. 2000; 49(11):1751-60. DOI: 10.2337/diabetes.49.11.1751. View

3.
Knowler W, Barrett-Connor E, Fowler S, Hamman R, Lachin J, Walker E . Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346(6):393-403. PMC: 1370926. DOI: 10.1056/NEJMoa012512. View

4.
Butler A, Janson J, Bonner-Weir S, Ritzel R, Rizza R, Butler P . Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2002; 52(1):102-10. DOI: 10.2337/diabetes.52.1.102. View

5.
Laybutt D, Glandt M, Xu G, Ahn Y, Trivedi N, Bonner-Weir S . Critical reduction in beta-cell mass results in two distinct outcomes over time. Adaptation with impaired glucose tolerance or decompensated diabetes. J Biol Chem. 2002; 278(5):2997-3005. DOI: 10.1074/jbc.M210581200. View